Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow up

Arthritis Research and Therapy

Volumn 14, Issue 1, 2012, Pages

  Houseman, Mark ^a   Potter, Catherine ^a   Marshall, Nicola ^b   Lakey, Rachel ^a   Cawston, Tim ^a   Griffiths, Ian ^b   Young Min, Steven ^c   Isaacs, John D ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b FREEMAN HOSPITAL   (United Kingdom)

^c QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; C TELOPEPTIDE OF TYPE II COLLAGEN; CARTILAGE OLIGOMERIC MATRIX PROTEIN; COLLAGEN TYPE 2; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; RHEUMATOID FACTOR; STROMELYSIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ACCURACY; ADULT; ARTICLE; COHORT ANALYSIS; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTOR VARIABLE; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; AGED; BLOOD; DISEASE COURSE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBSERVATION; PREDICTIVE VALUE; PROGNOSIS; RADIOGRAPHY; STATISTICAL MODEL; TIME;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBSERVATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TIME FACTORS;

EID: 84856582992     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3734     Document Type: Article

References (21)

1. Combe B. Progression in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2009, 23:59-69. 10.1016/j.berh.2008.11.006, 19233046.
2. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, Paulus HE, Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison JJ, Suarez Almazor M, Bridges SL, Chatham WW, Hochberg M, MacLean C, Mikuls T, Moreland LW, O'Dell J, Turkiewicz AM, Furst DE. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008, 59:762-784. 10.1002/art.23721, 18512708.
3. Emery P, McInnes B, van Vollenhoven R, Kraan MC. Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis. Rheumatology 2008, 47:392-398.
4. Young-Min S, Cawston T, Marshall N, Coady D, Christgau S, Saxne T, Robins S, Griffiths I. Biomarkers predict radiographic progression in early rheumatoid arthritis and perform well compared with traditional markers. Arthritis Rheum 2007, 56:3236-3247. 10.1002/art.22923, 17907159.
5. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000, 27:261-263.
6. Bruynesteyn K, van der Heijde D, Boers M, van der Linden S, Lassere M, van der Vleuten C. The Sharp/van der Heijde method out-performed the Larsen/Scott method on the individual patient level in assessing radiographs in early rheumatoid arthritis. J Clin Epidemiol 2004, 57:502-512. 10.1016/j.jclinepi.2003.10.014, 15196621.
7. Syversen SW, Goll GL, van der Heijde D, Landewé R, Gaarder PI, Odegård S, Haavardsholm EA, Kvien TK. Cartilage and bone biomarkers in rheumatoid arthritis: Prediction of 10-year radiographic progression. J Rheumatol 2009, 36:266-272. 10.3899/jrheum.080180, 19132792.
8. Van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Athritis Res Ther 2005, 7:949-958.
9. Syversen SW, Gaarder PI, Goll GL, Ødegård S, Haavardsholm EA, Mowinckel P, van der Heijde D, Landewé R, Kvien TK. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 2008, 67:212-217. 10.1136/ard.2006.068247, 17526555.
10. Alessandri C, Bombardieri M, Papa N, Cinquini M, Magrini L, Tincani A, Valesini G. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis 2004, 63:1218-1221. 10.1136/ard.2003.014647, 1754775, 15361374.
11. Vastesaeger N, Aletaha D, St Clair EW, Smolen JS. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. Rheumatology 2009, 48:1114-1121. 10.1093/rheumatology/kep155, 19589891.
12. Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ronday HK, Seys PE, Kerstens PJ, Huizinga TW, Dijkmans BA, Allaart CF. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann Rheum Dis 2010, 69:1333-1337. 10.1136/ard.2009.121160, 20498212.
13. Rengel Y, Ospelt C, Gay S. Proteinases in the joint: clinical relevance of proteinases in joint destruction. Arthritis Res Ther 2007, 9:221-231. 10.1186/ar2304, 2212555, 18001502.
14. Syversen SW, Landewe R, van der Heijde D, Bathon JM, Boers M, Bykerk VP, Fitzgerald O, Gladman DD, Garnero P, Geusens P, El-Gabalawy H, Inman RD, Kraus V, Kvien TK, Mease PJ, Ostergaard M, Ritchlin CJ, Tak PP, Taylor WJ, Maksymowych WP. Testing of the OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage in rheumatoid arthritis: a systematic literature search on 5 candidate biomarkers. J Rheumatol 2009, 36:1769-1784. 10.3899/jrheum.090262, 19671812.
15. Landewe R. Predictive markers in rapidly progressing rheumatoid arthritis. J Rheumatol 2007, 80:8-15.
16. Yamanaka H, Matsuda Y, Tanaka M, Sendo W, Nakajima H, Taniguchi A, Kamatani N. Serum matrix metalloproteinase 3 as a predictor of the degree of joint destruction during the six months after measurement, in patients with early rheumatoid arthritis. Arthritis Rheum 2000, 43:852-858. 10.1002/1529-0131(200004)43:4<852::AID-ANR16>3.0.CO;2-7, 10765930.
17. Posthumus MD, Limburg PC, Westra J, van Leeuwen MA, van Rijswijk MH. Serum matrix metalloproteinase 3 in early rheumatoid arthritis is correlated with disease activity and radiological progression. J Rheumatol 2000, 27:2761-2768.
18. Garnero P, Gineyts E, Christgau S, Finck B, Delmas PD. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis. Arthritis Rheum 2002, 46:21-30. 10.1002/1529-0131(200201)46:1<21::AID-ART10061>3.0.CO;2-Q, 11817593.
19. Green MJ, Gough AK, Devlin J, Smith J, Astin P, Taylor D, Emery P. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology 2003, 42:83-88. 10.1093/rheumatology/keg037, 12509618.
20. Tchetverikov I, Lard LR, DeGroot J, Verzijl N, TeKoppele JM, Breedveld FC, Huizinga TW, Hanemaaijer R. Matrix metalloproteinases-3, -8, -9 as markers of disease activity and joint damage progression in early rheumatoid arthritis. Ann Rheum Dis 2003, 62:1094-1099. 10.1136/ard.62.11.1094, 1754368, 14583574.
21. Mamehara A, Sugimoto T, Sugiyama D, Morinobu S, Tsuji G, Kawano S, Morinobu A, Kumagai S. Serum matrix metalloproteinase-3 as predictor of joint destruction in rheumatoid arthritis, treated with non-biological disease modifying anti-rheumatic drugs. Kobe J Med Sci 2010, 56:E98-107.